Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5691158 | Urology | 2017 | 29 Pages |
Abstract
The current series represents a “true-to-life” experience, wherein utilization patterns, attrition, and compliance issues are relevant factors impacting efficacy. PTT use with the Andropenis declined in both frequency and duration with subsequent injection series, and there was no significant difference in curve improvement or stretched penile length with a mean 10 hours of weekly concurrent PTT.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Matthew J. Ziegelmann, Boyd R. Viers, Brian D. Montgomery, Ross A. Avant, Joshua B. Savage, Landon W. Trost,